The anti-apoptotic molecule Bcl-2 is located in the mitochondrial and endoplasmic reticulum membranes as well as the nuclear envelope. Although its location has not been as rigorously de®ned, the pro-apoptotic molecule Bax appears to be mainly a cytosolic protein which translocates to the mitochondria upon induction of apoptosis. Here we identify a protease activity in mitochondria-enriched membrane fractions from HL-60 cells capable of cleaving Bax which is absent from the cytosolic fraction. Bax protease activity is blocked in vitro by cysteine protease inhibitors including E-64 which distinguishes it from all known caspases and granzyme B, both of which are involved in apoptosis. Protease activity is also blocked by inhibitors against the calciumactivated neutral cysteine endopeptidase calpain. Partial puri®cation of the Bax protease activity from HL-60 cell membrane fractions by column chromatography revealed that a calpain-like activity was the protease responsible for Bax cleavage. In addition, puri®ed calpain enzymes cleaved Bax in a calcium-dependent manner. Pretreatment of HL-60 cells with the speci®c calpain inhibitor calpeptin eectively blocked both drug-induced Bax cleavage and calpain activation, but not PARP cleavage or cell death. These results suggest that calpains and caspases are activated during drug-induced apoptosis and that calpains, along with caspases, may be involved in modulating cell death by acting selectively on cellular substrates.
Introduction
Apoptosis is regulated by the activity of several intracellular cysteine proteases of the ICE family (caspases) (Cohen, 1997; Porter et al., 1997) . All known caspase family members are located in the cytosol as zymogens where they become activated by apoptotic stimuli to form a signal transduction cascade (Cohen, 1997; Salvesen and Dixit, 1997) . The substrates for some caspases are known and include pro-interleukin-1b and interferon-g inducing factor for caspase-1, poly(ADP-ribose) polymerase (PARP), D4-GDI and U1-70 kDa for caspase-3 and lamin A for caspase-6 (Friedlander et al., 1996; Gu et al., 1996; Nicholson et al., 1995; Na et al., 1996; Casciola-Rosen et al., 1996; Orth et al., 1996) . It is widely believed that caspases are responsible for the destruction of cellular architecture leading to the distinct morphological appearance of apoptotic cells (Porter et al., 1997) .
Calpains are another family of cysteine proteases of which two isozymes are ubiquitously expressed, m-and m-calpain. These proteases also reside primarily in the cytosol, but translocate to cellular membranes where they appear to become activated (Kawasaki and Kawashima, 1996) . Indeed, many calpain substrates are located at or near cellular membranes and include the cytoskeleton associated proteins a-and b-spectrin and the a, b and g isoforms of the membrane associated enzyme protein kinase C (Croall et al., 1986; Kishimoto et al., 1989) . Other substrates not localized at membranes include the nuclear protein cyclin D1 (Choi et al., 1997) . Calpains have been implicated in many cellular processes including platelet aggregation, cytoskeletal reorganization during endocytosis and exocytosis and in several models of cell death including some instances of necrosis and apoptosis (Kawasaki and Kawashima, 1996; Geeraerts et al., 1991; Lee et al., 1991; Nichols et al., 1994; Nath et al., 1996; Squier and Cohen, 1997) .
Recent data have illustrated the central role of mitochondria in initiating cell death. Upon induction of apoptosis this organelle undergoes a series of changes that are crucial to the death program. One event, the mitochondrial permeability transition (PT), results from the opening of a large pore that is formed by a group of proteins located in the inner and outer mitochondrial membranes at sites where these membranes come into contact with each other (reviewed by Reed, 1997) . The PT leads to a disruption in the mitochondrial membrane potential (Dc) which in several apoptotic systems appears to be a very early, obligatory step in the death program (reviewed by Zamzami et al., 1997) and release of a protease (`apoptosis inducing factor', AIF) into the cytosol from the mitochondrial intermembrane space which is capable of initiating nuclear apoptotic events in vitro (Susin et al., 1996) . Another molecule released from the intermembrane space into the cytosol and capable of producing apoptotic changes is cytochrome c (Kluck et al., 1997; Yang et al., 1997) . Cytochrome c has been shown in vitro, along with caspase-9 and the human homolog of CED-4 in the presence of ATP, to be critical for activating the zymogen form of caspase-3 in the cytosol initiating the execution phase of the apoptotic cascade (Li et al., 1997) .
The anti-apoptotic molecule Bcl-2 is located in the membranes of the mitochondria, endoplasmic reticulum and nuclear envelope (Hockenbery et al., 1990; Krajewski et al., 1993; Akao et al., 1994) . The pro-apoptotic molecule Bax, however, appears to be localized primarily in the cytosol but upon induction of apoptosis rapidly translocates to the mitochondria Wolter et al., 1997; unpublished observations) . Members of the Bcl-2 family play key roles in the apoptotic events occuring at the mitochondria. Bcl-2 and Bcl-X L can block the disruption of the mitochondrial membrane potential as well as release of AIF and cytochrome c into the cytosol (Susin et al., 1996; Decaudin et al., 1997; Kim et al., 1997; Kluck et al., 1997; Yang et al., 1997; Zamzami et al., 1997) . Conversely, overexpression of Bax results in translocation of cytochrome c from the mitochondria to the cytosol in both yeast and mammalian cells (Manon et al., 1997; Rosse et al., 1998) . In addition Bax, Bcl-2 and Bcl-X L can form channels in synthetic lipid membranes (Antonsson et al., 1997; Minn et al., 1997; Schendel et al., 1997; Schlesinger et al., 1997) . However, the ability of Bax to form channels can be inhibited by Bcl-2 (Antonsson et al., 1997) . The fact that Bcl-2 is located at the mitochondria and that Bax translocates to this organelle upon induction of apoptosis, may help explain why mitochondria are in a critical position to control the fate of the cell.
Previously, we reported the appearance of an 18 kDa protein during drug-induced apoptosis in Bcells from chronic lymphocytic leukemia (B-CLL) patients which was recognized by anti-Bax antibody (Thomas et al., 1996) . Up-regulation of the 18 kDa Bax protein (p18) occurs following drug-induced apoptosis in normal human B-cells, in several hematopoietic cell lines including HL-60 promyelocytic leukemia cells, in several non-hematopoietic cell lines and in the presence of cycloheximide (data not shown). The fact that protein synthesis was not required for the appearance of the 18 kDa Bax protein and that it increased in amount over time in apoptotic cell cultures suggested proteolysis of the 21 kDa form of Bax (p21).
We report here that Bax is cleaved by a calciumactivated cysteine protease, calpain, in HL-60 cells during drug-induced apoptosis. Using an in vitro cleavage assay with HL-60 cell fractions enriched with mitochondrial membranes, we demonstrate that cleavage is blocked by inhibitors of cysteine proteases and calpains. In addition, we show that puri®ed calpain enzymes cleave Bax in a calcium dependent manner. Finally, pretreatment of HL-60 cells with the speci®c calpain inhibitor calpeptin eectively blocked both drug-induced Bax cleavage and calpain activation, yet PARP cleavage and cell death still occurred.
Results

p21 Bax is cleaved at the N-terminus during apoptosis
To determine whether p21 Bax was cleaved to form the 18 kDa protein, we induced apoptosis in HL-60 cells with the topoisomerase I inhibitor 9-AC and immunoprecipitated Bax from total cell lysates from drugtreated and untreated cells using anti-Bax speci®c antibody (Krajewski et al., 1994) (Figure 1 ). The immunoprecipitates were analysed on SDS ± PAGE and immunoblotted with antibodies raised to epitopes encoded by exon 2 (N20) or exon 3 (RAb) (Krajewski et al., 1994) of the 21 kDa Bax protein (Figure 1 ). The 21 kDa Bax protein present at time zero and 24 h after drug treatment was detected with both antibodies recognizing either determinants (Figure 1) . However, the 18 kDa protein present in cell lysates at 24 h after treatment could only be detected by the antibody speci®c for determinants encoded by exon 3. This result indicated cleavage in the N-terminus of Bax removing epitopes encoded by exon 2, but retaining the epitopes encoded by exon 3.
Bax cleavage enzyme activity in HL-60 membrane extracts
To identify the protease responsible for p21 Bax cleavage, we developed an in vitro assay to detect Bax cleavage enzyme activity (Figure 2 ).
35
S-methionine-labeled Bax was generated as a substrate by coupled in vitro transcription and translation of a fulllength human Bax cDNA and then incubated with dierent cell extracts. Since Bcl-2 is localized to the membranes of mitochondria (Hockenbery et al., 1990 ; Figure 1 Characterization of p21 Bax cleavage. (a) Schematic diagram of the 6 coding exons (I ± VI) of the Bax cDNA shows the location of the highly conserved Bcl-2 homology regions 1, 2 and 3 (BH1-3). Solid bars denote the epitopes encoded by exon 2 or exon 3 recognized by anti-Bax antibodies N20 (Santa Cruz) or RAb (Krajewski et al., 1994) , respectively. The underlined amino acids within exon 3 of the human Bax a sequence at positions #30 ± 37 and #45 ± 57 represent the 8-and 13-mer peptide sequences used to inhibit Bax protease activity. The Asp at positions Asp
33
, Asp 48 and Asp 53 are boxed. (b) Bax was immunoprecipitated from HL-60 cells at time zero (before treatment) or 24 h after 9-AC treatment using normal rabbit serum (NRS) or anti-Bax RAb and immunoblotted with RAb or the N20 antibody. Films were exposed for 1 min Krajewski et al., 1993; Akao et al., 1994) and Bax translocates to his organelle Wolter et al., 1997; unpublished observations) , we reasoned that the Bax protease activity might reside in the same compartment. HL-60 cells at time zero or 12 h after 9-AC treatment (T) were fractionated into cytosol (C) or heavy membranes (M) enriched for mitochondria and incubated with labeled Bax substrate (Figure 2a) . Cytosol extracts from both untreated and drug-treated HL-60 cells lacked protease activity. Heavy membrane extracts from drug-treated cells (M T ) contained protease activity that produced cleavage of p21 Bax to the 18 kDa protein (Figure 2a) . Surprisingly, enzyme activity was also present in heavy membrane extracts prepared from control untreated (M U ) HL-60 cells. Since the 18 kDa Bax cleavage product has never been detected in vivo in the absence of drug treatment (Figure 1) (Thomas et al., 1996; unpublished data) , this result suggested that detection of enzyme activity in membranes from untreated HL-60 cells in vitro could be due to protease activation or the loss of an inhibitor of protease activity during the cell fractionation procedure.
Protease inhibitor pro®le
To characterize the enzyme activity present in HL-60 heavy membrane extracts, protease inhibitors were screened for their ability to block p21 Bax cleavage (Figure 2b ). Enzyme activity was completely inhibited by the cysteine class of protease inhibitors E-64, leupeptin, IAA, NEM and substantially blocked by the tetrapeptide inhibitor of caspase-1, Ac-YVAD-cmk (Lazebnik et al., 1994) . The activity was not inhibited by the speci®c tetrapeptide inhibitor of caspase-3, Ac-DEVD-CHO (Nicholson et al., 1995) . Reports have shown that caspases are insensitive to E-64, but sensitive to NEM or IAA (Black et al., 1989; Thornberry et al., 1992; Lazebnik et al., 1994; Nicholson et al., 1995; Martins et al., 1997) . The calpain inhibitor I, ALLnL, at 10 and 100 mM also completely prevented Bax cleavage. In contrast, the serine class of protease inhibitors aprotinin, DFP, PMSF and TLCK did not block activity. However, the serine protease inhibitor TPCK did block activity. TPCK can block the activity of some types of endoproteinases that cleave after phenylalanine residues and can inhibit calpain-like activity in vitro (Pinter et al., 1992) . As discussed below, phenylalanine appears to be part of the cleavage site within Bax. The results of these inhibitor studies suggest that Bax cleavage is mediated by a membrane-associated, calpain-like cysteine protease which diers from the known caspases present in the cytosol and nuclei of HL-60 cells undergoing apoptosis such as caspase-2, -3 and -6 (Martins et al., 1997; Polverino and Patterson, 1997) .
Cleavage site of Bax
We next investigated the cleavage site within Bax. The most likely cleavage site is located within exon 3 (Figure 1 ) which would be consistent with the loss of 3 kDa in apparent molecular weight from 21 to 18 kDa. Since proteases in apoptotic pathways such as the caspases and the serine proteases granzyme B The protease inhibitor pro®le of Bax cleavage was characterized using heavy membrane extracts that were preincubated with buer alone (B) or with one of the following protease inhibitors: aprotinin (2 mg/ml), ALLnL (10 and 100 mM), DFP (100 mM), E-64 (10 mM), IAA (5 mM), NEM (5 mM), PMSF (100 mM), TLCK (100 mM), TPCK (100 mM), 1 mM of the tetrapeptide speci®c for caspase-1 (Ac-YVAD-cmk) or 10 mM of the tetrapeptide aldehyde speci®c for caspase-3 (Ac-DEVD-CHO) as described in the Materials and methods. Controls consisted of membrane extracts preincubated with the same volume of the inhibitor vehicles DMSO, EtOH and IsoproOH as well as buer alone with 35 S-methionine-labeled Bax (B). (c) to identify the cleavage site, heavy membrane extracts (10 mg) were incubated alone (M) or with 4 mM each of peptides spanning residues #45 ± 57 (ELALDPVPQDAST) or various 8-mer peptides spanning residues #30 ± 37 containing no substitutions (FIQDRAGR) RAGR) incubated with heavy membrane extracts for various periods of time as indicated. For (a ± d) the products of each reaction were examined by SDS ± PAGE and autoradiography as described in the Materials and methods. Abbreviations used: DFP, diisopropyl uorophosphate; E-64, trans-Epoxysuccinyl-L-leucylamido-(4-guanidine)butane; IAA, iodoacetic acid; NEM, N-ethylmaleimide; PMSF, phenylmethylsulfonyl¯uoride; TLCK, Na-p-Tosyl-L-lysine chloromethyl ketone; TPCK, N-Tosyl-L-phenylalanine choromethyl ketone; Ac-YVAD-cmk, Ac-Tyr-Val-Ala-Asp-chloromethylketone; Ac-DEVD-CHO, Ac-Asp-Glu-Val-Asp-CHO (aldehyde); DMSO, dimethylsulfoxide; EtOH, ethanol and IsoproOH, isopropanol cleave at Asp-X bonds (Cohen, 1997; Poe et al., 1991) , we examined whether cleavage might occur at one of three Asp residues located at positions Asp 33 , Asp 48 or Asp 53 using peptides spanning the putative cleavage sites from amino acids #30 ± 37 or amino acids #45 ± 57, respectively ( Figure 2c ). The peptide #30 ± 37 signi®cantly inhibited Bax cleavage whereas the peptide #45 ± 57 did not suggesting that the cleavage site was within the region spanning residues #30 ± 37 of Bax. substitutions. Finally, when the tetrapeptide sequence FIQD, spanning residues #30 ± 33, was tested for inhibition it completely blocked Bax cleavage activity in heavy membrane extracts. These data show that substitution of amino acids at positions 32 ± 35 within 8-mers spanning the 30 ± 37 region of Bax resulted in peptides that were still able to block Bax cleavage, albeit with varying degrees of ecacy, indicating a less essential role for these residues in recognition of Bax by the protease. In contrast, the tetrapeptide FIQD, which is complementary to the Bax sequence at residues 30 ± 33, completely inhibited cleavage suggesting that this region may play an important role in recognition of Bax by the protease.
Mutation of Asp 33 to Ala inhibited Bax cleavage
Since caspases require an Asp in the P1 position for eective cleavage of their substrates (Cohen, 1997) (Figure 2c ), indicate that the Asp 33 residue is not absolutely required for the protease activity to cleave Bax in vitro; this diers from the strict requirement of caspases for Asp in the P1 position (Cohen, 1997) .
Partial puri®cation of the Bax cleavage enzyme from HL-60 membrane extracts
To identify the protease responsible for Bax cleavage, heavy membrane extracts prepared from HL-60 cells were subjected to a Mono Q anion-exchange chromatography. The fractions were monitored for enzyme activity using a¯uorogenic peptide, Ac-FIQD-7-amino-4-methyl-coumarin (AMC), that contains the putative Bax cleavage site. As shown in Figure 3 , a single peak of enzyme activity was detected that eluted at approximately 500 mM NaCl. The fraction containing the highest enzyme activity was found to correlate with a protein band on a silver stained gel around 80 kDa which was absent from samples lacking protease activity (data not shown). This size is similar to the large subunit of both m-and m-calpain (Kawasaki and Kawashima, 1996) . Based on the results of the protease inhibitor pro®le which demonstrated that the Bax cleavage activity was completely inhibited by cysteine protease inhibitors and that the size corresponded to the large subunit of m-and mcalpain, we suspected that a calpain might be the enzyme responsible for Bax proteolysis. To test this, the fractions from the column were reassayed for calpain enzyme activity using the¯uorogenic calpain substrate N-Suc-Leu-Tyr-AMC (Kenney et al., 1994) . As illustrated in Figure 3 , a single peak of enzyme activity was also detected in the same fraction corresponding to the activity observed with Ac-FIQD-AMC. This activity was characterized with calpain selective inhibitors as summarized in Table 1 . The activity as measured by cleavage of Ac-FIQD-AMC was inhibited to a similar extent by calpain inhibitor I (ALLnL) and calpain inhibitor II (ALLM). Likewise, cleavage of N-Suc-Leu-Tyr-AMC was also blocked to a similar extent by both ALLnL and ALLM. These results taken together are consistent Figure 3 Puri®cation of Bax cleavage activity from HL-60 heavy membrane fractions. Isolation of heavy membranes, extraction of proteins and ion-exchange chromatography using a Mono Q anion exchange column to partially purify the activity was carried out as described in the Materials and methods. The Bax cleavage activity using both Ac-FIQD-AMC (open bar) and N-Suc-LeuTyr-AMC (shaded bar) as substrates was determined for each fraction. The enzyme activity is expressed as nanomoles of AMC released/min/fraction. Protein content (dotted line) is expressed as mg/fraction of each fraction as determined by using the BCA reagent (Pierce). The NaCl gradient (0.02 ± 1.0 M) is represented by the solid line The percent calpain-like protease activity was calculated as the ratio of¯uorescence units with inhibitor (each at 100 mM) over thē uorescence units without inhibitor (control). The data represent the average of three experiments and are expressed as means+s.e.m.
with the protease which cleaves Bax being a calpainlike enzyme.
Identi®cation of Bax as substrate for calpain in vitro
To determine whether Bax was a substrate for calpain, puri®ed m-and m-calpain enzymes were tested in the in vitro Bax cleavage assay for their ability to cleave 35 Slabeled p21 Bax to p18. As shown in Figure 4a , both mand m-calpain were able to eciently cleave Bax in a Ca 2+ -dependent manner. Fifty percent cleavage of p21 Bax to p18 occurred with both m-and m-calpain at 100 mM Ca 2+ and 500 mM Ca
2+
, respectively. Speci®c calpain inhibitors were tested for their ability to block Bax cleavage activity in heavy membrane extracts. The activity was substantially inhibited in the presence of 1, 10 and 100 mM of the calpain inhibitors ALLnL and ALLM (Figure 4b ). Both of these calpain inhibitors are also capable of inhibiting the proteosome (Rock et al., 1994) . To rule out the possibility of proteosome-mediated cleavage of Bax, we used the proteosome-speci®c inhibitor lactacystin (Fenteany et al., 1995) . Lactacystin failed to signi®cantly block Bax proteolysis at 1, 10 and 100 mM (Figure 4b ). These ®ndings further support the notion that Bax cleavage is mediated by a calpain.
Calpain mediated Bax cleavage in HL-60 cells
As noted above in Figure 2a , membranes prepared from non-apoptotic control HL-60 cells contained Bax cleavage activity which converted p21 Bax to p18. To determine whether calpain mediated Bax cleavage under these circumstances, cytosol (C) and heavy membranes (M) were prepared from HL-60 cells in the absence or presence of the inhibitors leupeptin and EGTA, both of which block calpains, in the lysis buer. Immunoblots of the cell lysates were probed with an anti-Bax antibody and an antibody which recognizes the 30 kDa subunit common to m-and mcalpain. As demonstrated in Figure 5 , cell fractionation in the absence of calpain inhibitors resulted in cleavage of p21 Bax to p18 at the heavy membranes whereas no cleavage was observed when cell fractionation was performed in the presence of inhibitors. Similarly, the 30 kDa small subunit of calpain underwent proteolysis to several dierent break-down products (BDPs) under conditions where cell fractionation was done in the absence of inhibitors. Autolysis of calpain subunits is used as a general marker for calpain activation (Kawasaki and Kawashima, 1996; Nath et al., 1996; Molinari and Carafoli, 1997) . These BDPs were not present when fractionation was carried out with leupeptin and EGTA. These observations taken together indicate that a calpain-like enzyme mediates Bax cleavage in vivo in HL-60 cells and explains why extracts from non-apoptotic cells possessed Bax cleavage activity in Figure 2a .
Calpain inhibitors block 9-AC induced Bax and calpain cleavage, but not PARP cleavage or cell death in HL-60 cells
To further con®rm that Bax cleavage was mediated by a calpain in vivo, the cell permeable calpain-speci®c inhibitor calpeptin (benzyloxycarbonyldipeptidyl; ZLeu-nLeuH, Mehdi, 1991) was tested for its ability to block both 9-AC-induced Bax cleavage in HL-60 cells and proteolysis of calpain to the BDPs indicative of activation of this enzyme (Kawasaki and Kawashima, 1996; Nath et al., 1996; Molinari and Carafoli, 1997) . Figure 6 is a representative experiment in which HL-60 cells untreated (data not shown) or pretreated with 30 mM calpeptin alone showed little to no p18 Bax cleavage product at 24 h ( Figure 6 ). In contrast, cultures challenged with the drug 9-AC alone for 24 h showed signi®cant conversion of p21 Bax to p18 (44.8+2.0%) as well as extensive proteolysis (46.9+8.5%) of the 30 kDa calpain subunit to the BDPs. However, HL-60 cells pretreated with calpeptin prior to 9-AC drug challenge showed a reduced amount of conversion of p21 Bax to p18 (11.1+2.9%) and proteolysis of the 30 kDa calpain To determine if Bax cleavage was the result of calpain activation during subcellular fractionation, non-apoptotic HL-60 cells were harvested and subjected to the fractionation procedure as described in the Materials and methods. Heavy membrane (M) and cytosol (C) fractions were generated either in the absence (7Inhib.) or the presence (+ Inhib.) of 10 mg/ml leupeptin and 1 mM EGTA in the lysis buer. The blots were probed with a polyclonal anti-Bax antibody or a monoclonal anti-calpain antibody recognizing the conserved 30 kDa small subunit of mand m-calpain subunit to BDPs (11.3+1.5%) after 24 h. Similar results were obtained in HL-60 cells that were pretreated with the calpain inhibitors ALLM or leupeptin (data not shown).
The ability of calpeptin pretreatment of HL-60 cells to block death was examined by measuring trypan blue exclusion at 24 h following 9-AC treatment. Treatment with 9-AC alone resulted in 41% (40.6+4.3%) of the cells scoring positive for uptake of the dye compared to 42% (41.5+3.9%) for cells that had been pretreated with calpeptin prior to drug treatment. Similar results were obtained when HL-60 cells were pretreated with calpain inhibitors ALLM and leupeptin (data not shown). Failure to block 9-AC induced cell death in HL-60 cells pretreated with calpain inhibitors prompted us to assess caspase activity by assaying for PARP cleavage. PARP is a substrate for caspase-3 and similar members of the caspase family and has been used as a general marker for caspase activity in several models of apoptosis (Cohen, 1997) . As shown in Figure 6 , pretreatment of HL-60 cells with calpeptin alone did not activate caspase activity since the amount of the full-length 116 kDa protein was similar at 0 and 24 h. However, when the cells were induced to undergo apoptosis with 9-AC treatment for 24 h, none of the full-length PARP remained compared to 0 h. Pretreatment of cells with calpeptin followed by 9-AC treatment for 24 h also resulted in the complete loss of full-length PARP compared to 0 h, similar to what was observed when cultures were treated with 9-AC alone. This result indicated that caspase-3-like proteases are activated during 9-AC induced death and that calpeptin does not prevent caspase activation. It appears that 9-AC induced apoptosis of HL-60 cells activates both calpains and caspases which are each capable of acting on speci®c cellular substrates.
Discussion
We have shown that Bax is a substrate for cleavage during drug-induced apoptosis of human B-leukemia cells in vivo. A consequence of this cleavage is the formation of p18 Bax homodimers (Thomas et al., 1996) . Using an in vitro assay and column chromatography, we have identi®ed the Bax cleavage enzyme activity in mitochondria-enriched membrane extracts from HL-60 cells as a calpain, a calcium-activated neutral cysteine endopeptidase. The protease inhibitor pro®le of calpains is consistent with the pro®le of the Bax cleaving activity in that both are cysteine proteases due to their mutual inhibition by E-64, leupeptin, IAA, and NEM. Both activities are also inhibited by calpain inhibitors ALLnL and ALLM, but not by the speci®c proteosome inhibitor lactacystin (Fenteany et al., 1995) . The partially puri®ed enzyme activity from extracts of HL-60 heavy membranes was active on the synthetic calpain substrate N-Suc-Leu-Tyr-AMC and was blocked by speci®c calpain inhibitors. Also, the molecular weight of a major protein band on a silverstained gel in the fraction showing the highest Bax cleavage activity using synthetic peptide substrate was consistent with the size of the large subunit of m-and m-calpains (data not shown). Both m-and m-calpain share a common 30 kDa small subunit, but have dierent 80 kDa large subunits (Kawasaki and Kawashima, 1996) . Furthermore, Bax could be cleaved in vitro from 21 kDa to 18 kDa with puri®ed m-and m-calpain. Finally, preparation of heavy membrane fractions (enriched with mitochondrial membranes) in the presence of calpain inhibitors prevented the appearance of calpain activation fragments as well as the Bax p18 cleavage product. This suggested that the Bax cleavage observed in these extracts was due to calpain activation within cells during subcellular fractionation.
Several lines of evidence suggest that the protease responsible for cleaving Bax is not a caspase. The ®rst observation is the association of the cleavage activity with cell fractions enriched with mitochondria. At present, all known caspases in HL-60 cells are found primarily in the cytosol and nucleus (Martins et al., 1997; Polverino and Patterson, 1997) . Second, puri®ed caspase-3 failed to cleave Bax in vitro (data not shown) and Ac-DEVD-CHO failed to block Bax cleavage in the in vitro assay (Figure 2b ) suggesting that caspase-3 is not responsible for Bax cleavage in HL-60 cells. Also, PARP cleavage occurred in apoptotic cells that had been pretreated with the calpain inhibitor calpeptin whereas Bax cleavage did not suggesting that activated caspase-3 was not cleaving Bax in vivo. Although Ac-YVAD-cmk could inhibit Bax cleavage in vitro at high concentrations, it is unlikely that caspase-1/ICE is responsible for cleavage since puri®ed caspase-1 failed to cleave Bax in vitro (data not shown) and does not become activated in HL-60 cells that have been stimulated to undergo apoptosis (Martins et al., 1997; Polverino and Patterson, 1997) . These results taken together indicate that Bax is a substrate for a calpain and not a caspase at the mitochondria or other organelles present in heavy membrane fractions. The presence of calpain-like activity at the mitochondria has been documented previously, but relevant substrates in vitro or in vivo have not been identi®ed to date (Beer et al., 1982; Tavares and Duque-Magalhaes, 1991; Aguilar et al., 1996) .
All known caspases cleave at Asp-X sequences and show strong P1 and P4 requirements for cleavage speci®city of their substrates (Cohen, 1997; Talanian et al., 1997) . In these experiments we have demonstrated Figure 6 Bax cleavage, calpain activation and PARP cleavage in the absense or presence of a speci®c calpain inhibitor in 9-AC treated HL-60 cells. HL-60 cells were pretreated with calpeptin (Z-LnLH) then treated with 9-AC to induce apoptosis as described in the Materials and methods. Whole cell lysates were made at 0 and 24 h after 9-AC treatment and subjected to Western blotting analysis using a polyclonal anti-Bax antibody, a monoclonal antibody that recognizes the conserved 30 kDa small subunit of m-and m-calpain and a monoclonal PARP antibody that recognizes the full-length 116 kDa PARP that Bax cleavage activity in vitro requires Asp 33 because mutation to Ala signi®cantly decreased cleavage activity. Unlike the caspases, however, the substitution of Asp 33 did not completely abrogate substrate cleavage suggesting that this Asp residue is not as critical for enzyme recognition as it is for the caspases to recognize and cleave the appropriate sites within their substrates. The tetrapeptide FIQD modeled on the putative Bax cleavage site completely eliminated cleavage activity in vitro indicating that this sequence may be important for recognition of Bax by a calpain. But the fact that peptides containing amino acid substitutions at or surrounding the Asp 33 in the cleavage site decreased with varying ecacy the ability of Bax to be cleaved in vitro is consistent with the less stringent sequence requirements of calpains for their substrates relative to the caspases (Wang et al., 1989; Talanian et al., 1997) .
At present, the mechanism by which Bax promotes apoptosis is unclear. However, recent data has begun to elucidate some of the potential roles that Bax may play in cell death. It appears that Bax mobilization to the mitochondria is a crucial early step in the death program. Using a fusion protein of Bax and green uorescent protein (GFP) in mammalian cells, Bax was found to reside diusely throughout the cytosol but translocated rapidly to the mitochondria when cells were treated with staurosporine . Prevention of Bax translocation to the mitochondria in this system by removal of the carboxy terminal tail prevented apoptosis .
The structures of the anti-apoptotic protein Bcl-X L alone and complexed with the death promoting molecule Bak have been deduced (Muchmore et al., 1996; Sattler et al., 1997) and can be used as a model for Bax. The BH1, BH2 and BH3 regions of Bcl-X L (Yin et al., 1994; Boyd et al., 1995; Chittenden et al., 1995; Zha et al., 1996a) were found to form an elongated hydrophobic cleft representing a possible binding site for other Bcl-2 family members (Muchmore et al., 1996) . The structure of Bcl-X L complexed with Bak demonstrated that an alpha helix containing the BH3 domain of Bak is crucial for binding the hydrophobic groove in Bcl-X L (Sattler et al., 1997) . In order for binding between these two molecules to take place, this helix would need to undergo a conformational change to allow for the BH3 domain of Bak to bind to the hydrophobic groove in Bcl-X L (Muchmore et al., 1996; Sattler et al., 1997) . The BH3 region of Bak is similar to that of Bax suggesting that Bax may undergo a similar structural change for its BH3 region to be involved in heterodimerization with anti-apoptotic molecules (Sattler et al., 1997) .
The BH3 domain of Bax is required for heterodimerization with Bcl-2, homodimerization and cell death (Boyd et al., 1995; Chittenden et al., 1995; Zha et al., 1996a,b) . Cleavage of Bax results in an 18 kDa form that still retains the BH3 domain (Figure 1) . It is possible, however, that cleavage of the 21 kDa form of Bax by a calpain results in structural changes within this molecule, analogous to Bak, which in turn allows for the disruption of interactions with Bcl-2 thereby precluding heterodimerization. We have observed that treatment of HL-60 cells with 9-AC resulted in the inability of Bcl-2 to be co-immunoprecipitated with Bax suggesting that the molecules were no longer capable of heterodimerizing (data not shown). Having liberated itself from Bcl-2, Bax would then be free perhaps to form p18 homodimers that we have observed associated with 9-AC induced cell death (Thomas et al., 1996) . It has been suggested that Bax homodimerization is a crucial event for this molecule to promote apoptosis (Yang and Korsmeyer, 1996; Zha et al., 1996b; Zha and Reed, 1997) .
The X-ray and NMR structure of uncomplexed Bcl-X L revealed that this protein resembles the membrane insertion domains of certain bacterial toxins especially diptheria toxin and the colicins (Muchmore et al., 1996) . The diptheria toxin translocation domain is believed to dimerize and form membrane pores (London, 1992; Muchmore et al., 1996) . Bcl-X L , along with Bcl-2 and Bax, have also shown the capacity to form ion conducting pores in synthetic lipid membranes Minn et al., 1997; Schlesinger et al., 1997; Antonsson et al., 1997) . The p18 Bax homodimerization observed during 9-AC induced death may be a prerequisite for pore formation similar to that of diptheria toxin. It is tempting to speculate that Bax pore formation at the mitochondria may trigger a membrane permeability transition (PT) and consequent disruption of the mitochondrial transmembrane potential (Dc) (Zamzami et al., 1997). Interestingly, the PT is also observed in necrosis where calpain activity at the mitochondria appears to be necessary for PT induction (Aguilar et al., 1996) . Alternatively, pores formed by Bax at the mitochondria could result in the release of cytochrome c from the intermembrane space into the cytosol (Kluck et al., 1997; Yang et al., 1997; Jurgensmeier et al., 1998) where it has been shown to be involved in activation of caspases (Devereaux et al., 1997; Li et al., 1997) . Supporting this notion is the observation that Bax overexpression in both yeast and mammalian cells results in cytochrome c translocation from the mitochondria to the cytosol (Manon et al., 1997; Jurgensmeier et al., 1998; Rosse et al., 1998) .
Calpains have been implicated in several models of apoptosis (Sarin et al., 1993; Squier et al., 1994; Nath et al., 1996; Vanags et al., 1996; Squier and Cohen, 1997) . Calpains cleave their substrates in a highly speci®c, but limited fashion (Wang et al., 1989) resulting in biologically active proteins (Kawasaki and Kawashima, 1996) . These proteases appear to be activated at cellular membranes where many of their substrates reside (Kawasaki and Kawashima, 1996) . Movement of Bax from the cytosol to the mitochondria Hsu et al., 1997; unpublished observations) would therefore position Bax for limited cleavage at that organelle by an activated calpain.
Induced expression of Bax in Bax-de®cient Jurkat cells resulted in an early decline in mitochondrial membrane potential as well as the generation of reactive oxygen species (ROS) (Xiang et al., 1996) . These ®ndings suggested that Bax localization at the mitochondria was responsible for initiating a cell death program at that organelle (Xiang et al., 1996) . Intriguingly, in this study Z-VAD-fmk inhibited caspase cleavage of nuclear as well as cytosolic substrates and prevented DNA fragmentation but failed to inhibit membrane permeability changes as measured by propidium iodide exclusion. Other protease inhibitors, including the calpain inhibitors ALLnL and ALLM, also failed to block Bax-induced death in Jurkat cells (Xiang et al., 1996) . Pretreatment of HL-60 cells with calpeptin and other calpain inhibitors did not completely abolish calpain activation or Bax cleavage that occurred with 9-AC treatment. Under these conditions 9-AC drug treatment induced PARP cleavage in both the absence and presence of calpeptin suggesting that both calpains and caspases were activated. The presence of both protease activities has also been observed in other apoptotic models (Nath et al., 1996; Vanags et al., 1996) . Thus, small amounts of limited proteolysis of Bax by a calpain may be sucient to set in motion a mitochondrial-based cell death program which directly controls the activation of caspases. Limited cleavage of Bax at the mitochondria by a calpain followed by pore formation may play a key role in the ability of this organelle to serve as the initiator of the downstream execution stage of apoptosis or necrosis. Future studies will examine the molecular function of Bax cleavage at the mitochondria.
Materials and methods
Immunoprecipitation and immunoblot analysis
Total cell lysates (200 mg) precleared for 2 h with protein Sepharose A (Pharmacia) were immunoprecipitated with 2 mg rabbit polyclonal anti-Bax antibody (Krajewski et al., 1994) for 4 h at 48C, followed by incubation with Sepharose A for 2 h at 48C. Immunoprecipitates were washed several times with Triton X-100/NP-40 lysis buer, resuspended in SDS sample buer, boiled for 5 min and centrifuged brie¯y at 300 g. Supernatants were electrophoresed on 12% SDS ± PAGE gels, transferred to PVDF membranes (Millipore) and immunoblotted as described (Thomas et al., 1996) with human-speci®c polyclonal rabbit anti-Bax antisera made against peptides corresponding to amino acids #43 ± 61 at 1 : 1000 (Krajewski et al., 1994) and with a rabbit polyclonal anti-Bax antibody corresponding to amino acids #11 ± 30 used at 1 : 50 (N20, Santa Cruz). Donkey anti-rabbit IgG (Amersham Life Science) HRPconjugated secondary antibody was used at 1 : 2000. Blots were developed using the ECL chemiluminescence detection kit (Amersham Life Science) and membranes were exposed to Hyper®lm-ECL for appropriate time intervals.
Subcellular fractionation
± 5610
7 HL-60 cells were washed twice in ice-cold PBS, resuspended in 2.5 ± 5.0 ml ice-cold lysis buer (10 mM HEPES pH, 7.4, 5 mM MgCl 2 42 mM KCl and 0.32 M sucrose), lysed with a 30 gauge needle until 495% of the cells were trypan blue positive and fractionated by dierential centrifugation to yield cytosol (C) and fractions enriched for mitochondrial membranes (heavy membranes, M) as described (Hockenbery et al., 1990) . Unless indicated, fractionation was carried out in the absence of protease inhibitors. Where noted, 10 mg/ml of leupeptin and 1 mM EGTA were added to the lysis buer. The heavy membrane fraction was solubilized in 100 ml of resuspension buer (10 mM HEPES, pH 7.4, 5 mM MgCl 2 , 42 mM KCl and 1% Triton X-100). The cytosol was precipitated with 6 volumes of cold acetone. After 20 min at 7208C the cytosol was centrifuged 5 min at 2000 g and the pellet was taken up in 100 ± 250 ml of resuspension buer. Drug treatment consisted of incubating cells for 12 h with 4 mM 9-amino-20(s)-camptothecin (9-AC, kindly provided by Dr M Potmesil).
In vitro cleavage assay
Bax a, subcloned into pcDNA3, was used for coupled in vitro transciption/translation in the presence of [ 35 S]methionine (NEN) according to the manufacturer's instructions (TNT, Promega). The Asp 33 of wild-type Bax in pcDNA3 was replaced with Ala 33 using a polymerase chain reaction (PCR) site-directed mutagenesis kit (ExSite, Stratagene) and con®rmed by DNA sequence analysis. The 35 S-methionine-labeled Bax substrate (0.5 ml) was incubated with 10 mg of cytosol or heavy membrane extracts for 2 h at 378C. For a control, labeled Bax substrate (0.5 ml) was incubated with 4.5 ml of assay buer (10 mM HEPES, pH 7.4, 1% Triton X-100). For the cleavage assay using puri®ed calpain enzymes, labeled Bax substrate (0.5 ml) was incubated with 100 ng of puri®ed m-or m-calpain (Chemicon) in assay buer containing dierent CaCl 2 concentrations in a total volume of 5 ml for 1 h at 378C. Heavy membrane extracts (10 mg) incubated with labeled Bax (0.5 ml) served as a positive control while assay buer (4.5 ml) incubated with labeled Bax (0.5 ml) was used as a negative control. The peptide inhibitor studies used heavy membrane extracts (10 mg) incubated with 4 mM of each peptide and labeled Bax (0.5 ml) for 2 h at 378C. For the protease inhibitor pro®le, heavy membrane extracts (10 mg) were preincubated with various concentrations of speci®c inhibitors or the solvents used for inhibitor solubilization for 45 min at 258C in assay buer in a total reaction volume of 4.5 ml then 0.5 ml of labeled Bax substrate was added and incubated for 2 h at 378C. All inhibitors were purchased from Sigma with the exception of Ac-YVADcmk (Calbiochem), Ac-DEVD-CHO (a gift from Dr A Zychlinsky) and lactacystin (a gift from Dr M Pagano). For the time course analysis of Bax cleavage, a master reaction of 35 ml was made consisting of heavy membrane extract, assay buer and either wild-type or Asp 33 mutant labeled Bax substrate from which 5 ml was removed at each time interval and boiled immediately to stop cleavage activity. For all experiments, the total reaction mixtures after incubation were mixed with an equal volume of 26SDS sample buer, boiled for 5 min at 1008C and analysed on 14% SDS ± PAGE gels. Autoradiography was performed for 1 ± 4 h at 7708C.
Column chromatography and¯uorogenic assays
Approximately 4.5 mg of heavy membrane fraction from 5610 8 HL-60 cells was generated as described above. The resulting membrane extract was centrifuged at 16 000 g for 20 min and the pH of the cleared supernatant, which retained virtually all of the activity in the¯uorogenic assays (data not shown, see below), was adjusted to pH 7.6 with 1 M Tris-HCl, pH 7.6 to a ®nal concentration of 20 mM Tris-HCl and to a ®nal NaCl concentration of 20 mM. The supernatant was applied to a Mono Q HR 5/5 anion exchange chromatography column (Pharmacia) that had been equilibrated with 20 mM Tris-HCl, pH 7.6, 20 mM NaCl (loading buer). Following washing with 4 ml loading buer, a 10 ml linear NaCl gradient from 0.02 ± 1.0 M in the same buer was used to elute the proteins. Fractions of 500 ml were collected at a rate of 1 ml/min. Protein estimated for each fraction was done using the BCA reagent (Pierce). All fractions were assayed for Bax cleavage enzyme activity in a¯uorogenic cleavage assay using either the custom Bax peptide Ac-FIQD-7-amino-4-methyl-coumarin (AMC) (Enzyme Systems Products) modeled on the putative Bax cleavage site or the synthetic calpain substrate N-Suc-Leu-Tyr-AMC (Sigma). The¯uorogenic assay consisted of 150 mM of¯uorescent substrate incubated with 10 ml of each fraction and assay buer (10 mM HEPES, pH 7.4, 1% Triton X-100) in a total volume of 100 ml for 2 h at 378C in 96-well plates. For the calpain substrate experiments, 100 mM CaCl 2 was added to the assay buer. For the inhibitor studies, 100 mM of the calpain inhibitors ALLnL and ALLM (both from Chemicon) or the inhibitor vehicle (water) were preincubated with the fractions for 15 min at 258C followed by the addition of substrate as described (Aguilar et al., 1996) . The plate was read in a Perkin Elmer LS50B luminescence spectrometer using an excitation wavelength of 380 nm and an emission wavelength of 460 nm. The amount of AMC released was determined from standard curves containing 0.0 ± 1.0 mmol of AMC. To determine the protein content of the fractions with enzyme activity, 5 ml of the fractions in the presence of 5% b-mercaptoethanol (Bio-Rad) were resolved on a 12% SDS ± PAGE gel and silver stained to visualize protein bands.
Inhibitor studies in HL-60 cells HL-60 cells (10 6 /well) were cultured in¯at-bottomed 6-well dishes (Nunclon) in 3 ml of RPMI-1640 medium (Cellgro) containing 10% fetal calf serum (Atlanta Biologicals), 100 U/ml penicillin, 100 mg/ml streptomycin, 1 mM sodium pyruvate and 2 mM glutamine (all from Gibco ± BRL) at 378C for 42 h prior to the addition of calpeptin (Calbiochem). HL-60 cells were either left untreated or pretreated with calpeptin (30 mM) or DMSO (calpeptin solvent) for 15 min at 378C and then were either left untreated, challenged with DMSO or the drug 9-AC (4 mM, dissolved in DMSO) for an additional 24 h at 378C. Cultures were harvested at the time of drug challenge (0 h) or 24 h later and subjected to trypan blue staining in triplicate. The percentage of dead cells was calculated as the number of trypan blue positive cells minus the control values at 24 h under each culture condition. Whole cell protein lysates were prepared for immunoblot analysis as described (Thomas et al., 1996) .
Immunoblot analysis
Quantitation of protein was carried out with the BCA reagent (Pierce). Equal amounts of protein (30 mg) in the presence of 5% b-mercaptoethanol (Bio-Rad) were subjected to gel electrophoresis using 8 or 12% SDS ± PAGE gels with the gels subsequently transferred to PVDF membranes (Millipore) by electroblotting (Thomas et al., 1996) . Immunoblotting was performed as described (Thomas et al., 1996) . Human-speci®c polyclonal rabbit anti-Bax antisera made against peptides corresponding to amino acids #43 ± 61 was used at 1 : 1000 (Krajewski et al., 1994) . A mouse monoclonal anti-calpain antibody (Chemicon) which recognizes the small 30 kDa subunit of m-and m-calpain was used at 1 : 1000. A mouse monoclonal anti-PARP antibody (clone C2-10, Pharmingen) recognizing the amino terminal 46 kDa DNA binding domain was used at 1 : 2000. Monoclonal sheep anti-mouse IgG and donkey anti-rabbit IgG (Amersham Life Science) HRP-conjugated secondary antibodies were used at 1 : 2000. Blots were developed using the ECL chemiluminescence detection kit (Amersham Life Science) and membranes were exposed to Hyper®lm-ECL for appropriate time intervals. Densitometry of immunoblot results was done using a Hewlett Packard Scanjet 2C scanner with analysis by Kodak Digital Science 1D software. The percent cleavage of Bax was calculated as the amount of p18 formed relative to the total amount of intact p21 and p18 after 24 h of drug treatment. The percent calpain proteolysis was measured as the amount of BDPs formed relative to the total amount of intact 30 kDa subunit and BDPs after 24 h of drug treatment. Experiments were done in triplicate and the data are expressed as means+standard error (s.e.m.).
